IOVA Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
99.3M
+39.0%
71.4M
-17.7%
86.8M
+28.6%
67.5M
+12.5%
60.0M
Cost of Revenue
43.6M
+2.6%
42.5M
-1.4%
43.1M
+12.0%
38.5M
-21.3%
48.9M
Gross Profit
55.7M
+92.6%
28.9M
-33.7%
43.7M
+50.7%
29.0M
+161.7%
11.1M
Operating Expenses
107.6M
-2.1%
110.0M
-6.1%
117.1M
-5.5%
123.9M
-0.8%
124.8M
R&D
58.9M
-5.8%
62.5M
-12.2%
71.2M
-5.3%
75.2M
-3.5%
77.9M
SG&A
39.3M
+0.8%
38.9M
+7.0%
36.4M
+5.3%
34.6M
-8.0%
37.6M
Operating Income
-51905000
+36.0%
-81043000
-10.3%
-73460000
+22.6%
-94901000
+16.6%
-113774000
EBITDA
-42405000
+41.5%
-72504000
-14.1%
-63532000
+21.6%
-81003000
+22.4%
-104424000
Net Income
-47315000
+40.1%
-79045000
-9.9%
-71904000
+21.2%
-91253000
+18.3%
-111658000
EPS (Basic)
$-0.11
+42.1%
$-0.19
-5.6%
$-0.18
+28.0%
$-0.25
+24.2%
$-0.33
EPS (Diluted)
$-0.11
+42.1%
$-0.19
-5.6%
$-0.18
+28.0%
$-0.25
+24.2%
$-0.33
Shares (Diluted)
450.2M
+7.6%
418.5M
+2.6%
408.0M
+12.1%
364.0M
+8.8%
334.5M
Iovance Biotherapeutics (IOVA) โ€” Financials